{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:26:06Z","timestamp":1782228366959,"version":"3.54.5"},"reference-count":188,"publisher":"Informa UK Limited","issue":"23","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.2217\/fon-2020-1147","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:41:25Z","timestamp":1624365685000},"page":"3111-3132","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["A Review of Emerging and Non-US FDA-Approved Topical Agents for the Treatment of Basal Cell Carcinoma"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-1006","authenticated-orcid":false,"given":"Natalie","family":"Kash","sequence":"first","affiliation":[{"name":"Department of Dermatology,Kansas City University-Graduate Medical Education Consortium\/Advanced Dermatology &amp; Cosmetic Surgery Orlando Program,\rMaitland, FL32751, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-6302","authenticated-orcid":false,"given":"Sirunya","family":"Silapunt","sequence":"additional","affiliation":[{"name":"Department of Dermatology,University of Texas McGovern Medical School at Houston,\rHouston, TX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.060"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/014107688307600413"},{"key":"e_1_3_3_4_1","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","author":"National Comprehensive Cancer Network","year":"2021","unstructured":"National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Basal Cell Skin Cancer Version 2.2021 (2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nmsc.pdf","journal-title":"Basal Cell Skin Cancer Version 2.2021"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03259.x"},{"key":"e_1_3_3_6_1","unstructured":"US FDA . Aldara. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20723s016lbl.pdf"},{"key":"e_1_3_3_7_1","unstructured":"US FDA . Efudex topical solutions and cream. (2005). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/016831s049lbl.pdf"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930030314"},{"key":"e_1_3_3_9_1","unstructured":"FDA . Carac\u00ae cream 0.5%. (2017). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20985slr004_carac_lbl.pdf"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1965.01600160066015"},{"issue":"8","key":"e_1_3_3_11_1","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson M","year":"1999","unstructured":"Johnson M , HageboutrosA, WangKet al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res.5(8), 2006\u20132011 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F"},{"issue":"3","key":"e_1_3_3_13_1","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto C","year":"1996","unstructured":"Takimoto C , LuZ, ZhangRet al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res.2(3), 477\u2013481 (1996).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113308"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507253130407"},{"issue":"6","key":"e_1_3_3_16_1","first-page":"318","article-title":"Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study","volume":"85","author":"Quirk G","year":"2010","unstructured":"Quirk G , GebauerK, De\u2019ambrosisBet al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis85(6), 318\u2013324 (2010).","journal-title":"Cutis"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.10.422"},{"issue":"6","key":"e_1_3_3_18_1","first-page":"677","article-title":"Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study from Europe","volume":"18","author":"Gollnick H","year":"2008","unstructured":"Gollnick H , CgB, FrankRet al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study from Europe. Eur. J. Dermatol.18(6), 677\u2013682 (2008).","journal-title":"Eur. J. Dermatol."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1526-3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.05069.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1967.126"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.291"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11061.x"},{"issue":"4","key":"e_1_3_3_24_1","first-page":"433","article-title":"5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcomes, and patient satisfaction","volume":"33","author":"Gross K","year":"2007","unstructured":"Gross K , KircikL, KricoarianG. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcomes, and patient satisfaction. Dermatol. Surg.33(4), 433\u2013440 (2007).","journal-title":"Dermatol. Surg."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70530-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.019"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-12-19"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.193078"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13066"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.033"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.043"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1965.62"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70261-6"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06486.x"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113689"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126215"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.11.066"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13299"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.9.1165"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.022"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1985.01660020065019"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1966.96"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250782"},{"key":"e_1_3_3_44_1","unstructured":"US FDA . Highlights of Prescribing Information. Reference ID: 3985290. (2016). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202833s007lbl.pdf."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12148"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.6.796"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S109531"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12438"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14046"},{"issue":"5","key":"e_1_3_3_50_1","first-page":"317","article-title":"A scarring reaction to the treatment of basal cell carcinoma with ingenol mebutate","volume":"12","author":"Nguyen NM","year":"2014","unstructured":"Nguyen NM , TremaineAM, ZacharyCB. A scarring reaction to the treatment of basal cell carcinoma with ingenol mebutate. Skinmed12(5), 317\u2013318 (2014).","journal-title":"Skinmed"},{"key":"e_1_3_3_51_1","volume-title":"Conference 2015 Fall Clinical Dermatology Conference.","author":"Alston D","year":"2015","unstructured":"Alston D , ChowM. Ingenol mebutate gel 0.015% for the topical treatment of nodular basal cell carcinoma. Presented at: Conference 2015 Fall Clinical Dermatology Conference.Las Vegas, NV, USA (2015)."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0802a12"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12399"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1159\/000447394"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.16.05271-8"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001225"},{"issue":"11","key":"e_1_3_3_57_1","first-page":"S3","article-title":"Ingenol mebutate topical gel a status report on clinical use beyond actinic keratosis","volume":"9","author":"Del Rosso J","year":"2016","unstructured":"Del Rosso J . Ingenol mebutate topical gel a status report on clinical use beyond actinic keratosis. J. Clin. Aesthet. Dermatol.9(11), S3\u2013S11 (2016).","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"e_1_3_3_58_1","unstructured":"Spelman L RosenR KnudsenKet al. Ingenol mebutate with full occlusion effectively treated superficial BCC. Presented at: EADO Congress Vinius Lithuania (2014)."},{"key":"e_1_3_3_59_1","volume-title":"72nd Annual American Academy of Dermatology Meeting.","author":"Freeman M","year":"2014","unstructured":"Freeman M , RosenR, ZibertJet al. Ingenol mebutate gel topically applied under occlusion to superficial basal cell carcinoma is efficacious compared with marginal effect in seborrheic keratosis. Presented at:72nd Annual American Academy of Dermatology Meeting.Denver, CO, USA (March 21\u201325, 2014)."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2010.00626.x"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13229"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15907"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.050"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2529"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03363.x"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(87)90081-4"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(91)90140-D"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3370"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.48"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1541"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1973.01620270041010"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70241-7"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1993.tb00346.x"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01965758"},{"issue":"4","key":"e_1_3_3_75_1","first-page":"485","article-title":"The results of topical application of 13-cis-retinoic acid on basal cell carcinoma. A correlation of the clinical effect with histopathological examination and serum retinol level","volume":"34","author":"Sankowski A","year":"1987","unstructured":"Sankowski A , JanikP, JeziorskaMet al. The results of topical application of 13-cis-retinoic acid on basal cell carcinoma. A correlation of the clinical effect with histopathological examination and serum retinol level. Neoplasma34(4), 485\u2013489 (1987).","journal-title":"Neoplasma"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912023412312"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12488.x"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22414.x"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06044.x"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200502000-00018"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0305"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.014"},{"key":"e_1_3_3_83_1","first-page":"003","article-title":"Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways","volume":"3","author":"Cuevas P","year":"2011","unstructured":"Cuevas P , AnguloJ, Cuevas-BourdierAet al. Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways. J. Cancer Sci. Ther.S3, 003 (2011).","journal-title":"J. Cancer Sci. Ther."},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.551108"},{"issue":"5","key":"e_1_3_3_85_1","first-page":"202","article-title":"Topical treatment of basal cell carcinoma with neomycin","volume":"10","author":"Cuevas P","year":"2005","unstructured":"Cuevas P , ArrazolaJM. Topical treatment of basal cell carcinoma with neomycin. Eur. J. Med. Res.10(5), 202\u2013203 (2005).","journal-title":"Eur. J. Med. Res."},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S127040"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12753"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00397.x"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250752"},{"issue":"11","key":"e_1_3_3_90_1","first-page":"3036","article-title":"Topical immunotherapy of basal cell carcinomas with dinitrochlorobenzene","volume":"33","author":"Levis WR","year":"1973","unstructured":"Levis WR , KraemerKH, KlinglerWG, PeckGL, TerryWD. Topical immunotherapy of basal cell carcinomas with dinitrochlorobenzene. Cancer Res.33(11), 3036\u20133042 (1973).","journal-title":"Cancer Res."},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1159\/000309395"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.12.1593"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197408)34:2<250::AID-CNCR2820340204>3.0.CO;2-X"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1975.tb29227.x"},{"issue":"6","key":"e_1_3_3_95_1","first-page":"562","article-title":"Topical 1% cidofovir for the treatment of basal cell carcinoma","volume":"12","author":"Calista D","year":"2002","unstructured":"Calista D . Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur. J. Dermatol.12(6), 562\u2013564 (2002).","journal-title":"Eur. J. Dermatol."},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1965.01600150083016"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1979.tb05603.x"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-003-0404-9"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.003"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15364"},{"key":"e_1_3_3_101_1","first-page":"329","article-title":"Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas","volume":"810","author":"Albert B","year":"2014","unstructured":"Albert B , HahnH. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas. Adv. Exp. Med. Biol.810, 329\u2013341 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0422"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-10-0285"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07856.x"},{"issue":"1","key":"e_1_3_3_105_1","first-page":"30","article-title":"CXCR-4 and COX-2 expression in basal cell carcinomas and well-differentiated squamous cell carcinomas of the skin; their relationship with tumor invasiveness and histological subtype","volume":"31","author":"Sivrikoz ON","year":"2015","unstructured":"Sivrikoz ON , UyarB, DagF, TasliF, SanalSM. CXCR-4 and COX-2 expression in basal cell carcinomas and well-differentiated squamous cell carcinomas of the skin; their relationship with tumor invasiveness and histological subtype. Turk. Patoloji Derg.31(1), 30\u201335 (2015).","journal-title":"Turk. Patoloji Derg."},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108598"},{"key":"e_1_3_3_107_1","unstructured":"US FDA . Solaraze\u00ae gel. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021005s013lbl.pdf"},{"issue":"1","key":"e_1_3_3_108_1","first-page":"1","article-title":"Topical therapy for superficial basal cell carcinoma","volume":"2","author":"Sutton L","year":"2017","unstructured":"Sutton L , ShimizuI. Topical therapy for superficial basal cell carcinoma. Int. J. Clin. Exp. Dermatol.2(1), 1\u20134 (2017).","journal-title":"Int. J. Clin. Exp. Dermatol."},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2002.470308_11.x"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2006.0645f.x"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.08.020"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2004.0424g.x"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1185"},{"key":"e_1_3_3_114_1","unstructured":"US FDA . Veregen. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021902s017lbl.pdf"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15071442"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-962621"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(90)90121-D"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(90)90122-E"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-962612"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(95)00186-7"},{"issue":"1","key":"e_1_3_3_121_1","first-page":"403","article-title":"Extract of Solanum muricatum (pepino\/CSG) inhibits tumor growth by inducing apoptosis","volume":"19","author":"Ren W","year":"1999","unstructured":"Ren W , TangDG. Extract of Solanum muricatum (pepino\/CSG) inhibits tumor growth by inducing apoptosis. Anticancer Res.19(1A), 403\u2013408 (1999).","journal-title":"Anticancer Res."},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2503"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/39918"},{"issue":"12","key":"e_1_3_3_124_1","first-page":"2336","article-title":"Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma","volume":"57","author":"Unden AB","year":"1997","unstructured":"Unden AB , ZaphiropoulosPG, BruceK, ToftgardR, Stahle-BackdahlM. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res.57(12), 2336\u20132340 (1997).","journal-title":"Cancer Res."},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/15242"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/73417"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3438"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5313.817"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00222.x"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0996-78"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5268.1668"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81268-4"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/34201"},{"issue":"9","key":"e_1_3_3_134_1","first-page":"1798","article-title":"Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system","volume":"58","author":"Reifenberger J","year":"1998","unstructured":"Reifenberger J , WolterM, WeberRGet al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res.58(9), 1798\u20131803 (1998).","journal-title":"Cancer Res."},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S130910"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10157"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.02.027"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9525"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.05.033"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eaca65"},{"issue":"7","key":"e_1_3_3_141_1","first-page":"186","article-title":"Is Solcoderm suitable for treating malignant skin tumors?","volume":"117","author":"Moscona R","year":"1989","unstructured":"Moscona R , UllmannY, MalbergerE, HirshowitzB. Is Solcoderm suitable for treating malignant skin tumors?Harefuah117(7\u20138), 186\u2013189 (1989).","journal-title":"Harefuah"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2077.104914"},{"issue":"11","key":"e_1_3_3_143_1","first-page":"1017","article-title":"Focal treatment of acne scars with trichloroacetic acid: chemical reconstruction of skin scars method","volume":"28","author":"Lee JB","year":"2002","unstructured":"Lee JB , ChungWG, KwahckH, LeeKH. Focal treatment of acne scars with trichloroacetic acid: chemical reconstruction of skin scars method. Dermatol. Surg.28(11), 1017\u20131021 (2002).","journal-title":"Dermatol. Surg."},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9872.1000198"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.09.014"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2016.1666"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23497.x"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI22800"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164102101200069"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164102101200375"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164103101201030"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164103101202165"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5668"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa5004"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804226105"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2070-8"},{"issue":"2","key":"e_1_3_3_157_1","first-page":"14","article-title":"A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream","volume":"70","author":"Levy S","year":"2002","unstructured":"Levy S , FurstK, ChernW. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Cutis70(Suppl. 2), 14\u201321 (2002).","journal-title":"Cutis"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80078-3"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80077-1"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2015.03.007"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2010.07.001"},{"issue":"4","key":"e_1_3_3_162_1","first-page":"517","article-title":"Nanoparticles as drug carrier system of 5-fluorouracil in local treatment of patients with superficial basal cell carcinoma","volume":"10","author":"Hadjikirova M","year":"2005","unstructured":"Hadjikirova M , TroyanovaP, SimeonovaM. Nanoparticles as drug carrier system of 5-fluorouracil in local treatment of patients with superficial basal cell carcinoma. J. BUON10(4), 517\u2013521 (2005).","journal-title":"J. BUON"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2000.99227.x"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2013.12.013"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1969.47"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2003.10.025"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12908"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119808"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.10.007"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.11.033"},{"key":"e_1_3_3_171_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2011.1524"},{"key":"e_1_3_3_172_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.882449"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2006.00222.x"},{"issue":"1","key":"e_1_3_3_174_1","first-page":"S15","article-title":"Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report","volume":"7","author":"Rigel D","year":"2008","unstructured":"Rigel D , TorresA, ElyH. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J. Drugs Dermatol.7(1 Suppl. 1), S15\u2013S16 (2008).","journal-title":"J. Drugs Dermatol."},{"issue":"9","key":"e_1_3_3_175_1","first-page":"910","article-title":"Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage","volume":"6","author":"Neville J","year":"2007","unstructured":"Neville J , WillifordP, JorizzoJ. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J. Drugs Dermatol.6(9), 910\u2013914 (2007).","journal-title":"J. Drugs Dermatol."},{"issue":"1","key":"e_1_3_3_176_1","first-page":"S7","article-title":"A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma","volume":"7","author":"Tillman DJ","year":"2008","unstructured":"Tillman DJ , CarrollM. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J. Drugs Dermatol.7(1 Suppl. 1), S7\u2013S14 (2008).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_3_177_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200601000-00011"},{"issue":"1","key":"e_1_3_3_178_1","first-page":"24","article-title":"Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study","volume":"35","author":"Butler D","year":"2009","unstructured":"Butler D , ParekhP, LenisA. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol. Surg.35(1), 24\u201329 (2009).","journal-title":"Dermatol. Surg."},{"key":"e_1_3_3_179_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10924.x"},{"key":"e_1_3_3_180_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418758973"},{"key":"e_1_3_3_181_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-199509000-00013"},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000814"},{"key":"e_1_3_3_183_1","first-page":"93080Q","article-title":"Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models","volume":"9308","author":"Rollakanti K","year":"2015","unstructured":"Rollakanti K , AnandS, MaytinEV. Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models. Proc. SPIE Int. Soc. Opt. Eng.9308, 93080Q (2015).","journal-title":"Proc. SPIE Int. Soc. Opt. Eng."},{"key":"e_1_3_3_184_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23013"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1609449"},{"key":"e_1_3_3_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.01.032"},{"key":"e_1_3_3_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.05.002"},{"key":"e_1_3_3_188_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1574-x"},{"key":"e_1_3_3_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(02)00178-3"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:53Z","timestamp":1719124973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":188,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/fon-2020-1147"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1147","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}